Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.

Authors: Baptista, Marco A S  Dave, Kuldip D  Frasier, Mark A  Sherer, Todd B  Greeley, Melanie  Beck, Melissa J  Varsho, Julie S  Parker, George A  Moore, Cindy  Churchill, Madeline J  Meshul, Charles K  Fiske, Brian K 
Citation: Baptista MA, etal., PLoS One. 2013 Nov 14;8(11):e80705. doi: 10.1371/journal.pone.0080705. eCollection 2013.
Pubmed: (View Article at PubMed) PMID:24244710
DOI: Full-text: DOI:10.1371/journal.pone.0080705

The objective of this study was to evaluate the pathology time course of the LRRK2 knockout rat model of Parkinson's disease at 1-, 2-, 4-, 8-, 12-, and 16-months of age. The evaluation consisted of histopathology and ultrastructure examination of selected organs, including the kidneys, lungs, spleen, heart, and liver, as well as hematology, serum, and urine analysis. The LRRK2 knockout rat, starting at 2-months of age, displayed abnormal kidney staining patterns and/or morphologic changes that were associated with higher serum phosphorous, creatinine, cholesterol, and sorbitol dehydrogenase, and lower serum sodium and chloride compared to the LRRK2 wild-type rat. Urinalysis indicated pronounced changes in LRRK2 knockout rats in urine specific gravity, total volume, urine potassium, creatinine, sodium, and chloride that started as early as 1- to 2-months of age. Electron microscopy of 16-month old LRRK2 knockout rats displayed an abnormal kidney, lung, and liver phenotype. In contrast, there were equivocal or no differences in the heart and spleen of LRRK2 wild-type and knockout rats. These findings partially replicate data from a recent study in 4-month old LRRK2 knockout rats and expand the analysis to demonstrate that the renal and possibly lung and liver abnormalities progress with age. The characterization of LRRK2 knockout rats may prove to be extremely valuable in understanding potential safety liabilities of LRRK2 kinase inhibitor therapeutics for treating Parkinson's disease.

Annotation

Phenotype Annotations
Experimental Data Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 12880447
Created: 2017-05-08
Species: All species
Last Modified: 2017-05-08
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.